Company intelligence / Profile preview

Polytherapeutics

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

PolyTherics platforms have demonstrated promising pre-clinical results in extending circulation half-life and reducing immunogenicity of conjugated biologics, as well as targeting alpha-fetoprotein for hematologic malignancies

Therapeutic areas: OncologyHematology
Modalities: Protein drug conjugateAntibody-drug conjugatePolymer-drug conjugate therapy (PEGylation, Polypeg scaffolds)
Industry: Biotech

Partnerships

Biotecnol Ltd. (ThioBridge ADC co-development)Ascension Healthcare (hemophilia A program)Imperial Innovations (investment/commercialization)

Beyond the preview

Go deeper on Polytherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polytherapeutics.

Explore the full profile